Biosimilars

Renflexis is indicated for the same inflammatory conditions as reference drug infliximab.

Renflexis is a biosimilar of Remicade, which treats inflammatory conditions, including Crohn’s disease, rheumatoid arthritis, and psoriatic arthritis.

Biosimilar to trastuzumab (Herceptin) observed to have no clinically significant differences than the reference product.

Trastuzumab is indicated as an adjuvant therapy for HER2-positive breast cancer, along with metastatic breast and gastric cancers.

New report provides insight into patient awareness and attitudes towards biosimilars.

Biosimilars have the potential to achieve billions in savings, but significant challenges remain.

Express Scripts reports that the emergence of 11 biosimilars could result in $250 billion in savings over the next decade.

Study finds the current reimbursement model for biosimilars needs to be adjusted to improve uptake.

Filgrastim-sndz (Zarxio) is covered by 94% of employer-sponsored health plans.

The ability of manufacturers to convey the efficacy and safety of a new biosimilar is crucial.

Boehringer Ingelheim seeks to launch its biosimilar to Humira.

Changing from a biologic to a biosimilar can create insecurity among patients with RA.

Jonathan Ogurchak, PharmD, CSP, vice president of Business Operations at PANTHERx Specialty Pharmacy, discusses how to increase the utilization of biosimilars across the industry.

Erelzi (etanercept) indicated to treat multiple inflammatory conditions.

Payers and providers may be less likely to encourage the use of biosimilars due to multiple concerns.

There are nearly 1000 products in development for dermatological conditions.

AstraZeneca and GlaxoSmithKline are key players in the COPD market.

Chronic obstructive pulmonary disease market projected to reach $14.1 billion by 2025.

The guide seeks to provide health care professionals with reference information on the science and regulation underpinning biosimilar use.

Top news of the day from across the health care landscape.

Another state passes legislation to increase uptake of biosimilars.

Jonathan Van Lare, PharmD, director of Pharmacy Advantage, discusses the growth of biosimilars in specialty pharmacy.

The World Health Organization recently announced plans to launch a pilot program for prequalifying biosimilars.

World Health Organization plans to launch a biosimilar prequalification program.

FDA authorizes an omalizumab (Xolair) biosimilar to commence clinical trials.

GBR 310 is a recombinant DNA-derived monoclonal antibody for the treatment of allergic asthma and chronic idiopathic urticaria.

Increased development of biosimilars will drive the need for analytical instrument analyzers, report finds.

Suzette DiMascio, CHE, CMCE, CPC, president and CEO of CSI Specialty Group, discusses the potential impact of biosimilars on specialty pharmacy.

Amgen is claiming patent infringement against Sanofi and Regeneron based on the biological mechanisms of dupilumab (Dupixent).

Litigation to continue surrounding biological mechanisms of dupilumab (Dupixent).